We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
-19.33%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$335M
AUM Growth
-$24.9M
Cap. Flow
+$60.4M
Cap. Flow %
18.05%
Top 10 Hldgs %
58.78%
Holding
55
New
11
Increased
22
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$17.8M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$11.9M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$11.5M
4
ACCD
Accolade Inc
ACCD
+$11.3M
5
ADCT icon
ADC Therapeutics
ADCT
+$10M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$12.3M
2
GH icon
Guardant Health
GH
+$9.7M
3
KURA icon
Kura Oncology
KURA
+$6.79M
4
KIDS icon
OrthoPediatrics
KIDS
+$6.68M
5
PFE icon
Pfizer
PFE
+$5.97M

Sector Composition

Rank Sector Weight
1 Healthcare 95.26%
2 Industrials 4.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
26
Neurocrine Biosciences
NBIX
$17.7B
$3.72M 1.11%
27,000
-3,500
-11% -$480K
RLAY icon
27
Relay Therapeutics
RLAY
$4.02B
$2.51M 0.75%
385,000
-65,000
-14% -$444K
BCRX icon
28
BioCryst Pharmaceuticals
BCRX
$2.37B
$2.46M 0.74%
398,700
-1,001,300
-72% -$5.53M
CVS icon
29
CVS Health
CVS
$137B
$2.36M 0.71%
+40,000
New +$2.5M
MDT icon
30
Medtronic
MDT
$107B
$2.36M 0.71%
30,000
-150,000
-83% -$12.3M
VINC
31
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$2.02M 0.6%
+124,421
New +$3.12M
INSP icon
32
Inspire Medical Systems
INSP
$1.42B
$1.87M 0.56%
+14,000
New +$2.65M
FNA
33
DELISTED
Paragon 28, Inc.
FNA
$1.79M 0.53%
+261,400
New +$2.21M
UHS icon
34
Universal Health Services
UHS
$9.43B
$1.73M 0.52%
9,373
-20,627
-69% -$3.65M
PRVA icon
35
Privia Health
PRVA
$3.21B
$1.67M 0.5%
96,065
+51,065
+113% +$905K
MURA
36
DELISTED
Mural Oncology
MURA
$1.49M 0.45%
475,458
+75,458
+19% +$278K
ADUS icon
37
Addus HomeCare
ADUS
$2.14B
$1.45M 0.43%
+12,500
New +$1.34M
TECX
38
Tectonic Therapeutic
TECX
$573M
$1.11M 0.33%
67,461
+20,251
+43% +$324K
LENZ
39
LENZ Therapeutics
LENZ
$172M
$1.03M 0.31%
59,542
-5,458
-8% -$95.3K
TXG icon
40
10x Genomics
TXG
$5.87B
$953K 0.29%
49,021
+19,021
+63% +$498K
OVID icon
41
Ovid Therapeutics
OVID
$435M
$827K 0.25%
1,075,000
+91,800
+9% +$255K
IMNM icon
42
Immunome
IMNM
$2.52B
$787K 0.24%
+65,000
New +$1.02M
RNTX
43
Rein Therapeutics
RNTX
$67.7M
$734K 0.22%
+265,000
New +$1.09M
IMRX icon
44
Immuneering
IMRX
$279M
$704K 0.21%
+550,000
New +$904K
BMEA icon
45
Biomea Fusion
BMEA
$90.4M
$560K 0.17%
124,377
+49,377
+66% +$502K
KZR
46
DELISTED
Kezar Life Sciences
KZR
$33.6K 0.01%
5,608
-90,752
-94% -$690K
ABSI icon
47
Absci
ABSI
$1.28B
– –
-25,000
Closed -$142K
AGIO icon
48
Agios Pharmaceuticals
AGIO
$2.16B
– –
-25,000
Closed -$731K
BBSI icon
49
Barrett Business Services
BBSI
$976M
– –
-96,000
Closed -$3.04M
CRBP icon
50
Corbus Pharmaceuticals
CRBP
$170M
– –
-100,617
Closed -$3.95M
1
2
3

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q2 2024 Portfolio in Review

As of Q2 2024, Prosight Management held 55 positions worth $335M, down 6.9% from $359M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Prosight Management deployed $60.4M of net new capital in Q2 2024, opening 11 new positions and adding to 22 existing holdings. Its largest new stake was Syndax Pharmaceuticals: 551,544 shares worth $11.3M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 97% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Medtronic, an estimated $12.3M trimmed.

  • Prosight Management's largest Q2 2024 buy was Syndax Pharmaceuticals: 551,544 shares worth $11.3M.
  • Prosight Management added most to Zimmer Biomet in Q2 2024, an estimated $17.8M increase.
  • Prosight Management's biggest Q2 2024 reduction was Medtronic, cutting an estimated $12.3M.
  • Prosight Management fully exited Guardant Health in Q2 2024, selling an estimated $9.7M.
  • Prosight Management's ten largest holdings make up 59% of its $335M portfolio in Q2 2024.
  • Prosight Management opened 11 new positions and closed 9 in Q2 2024.
  • Prosight Management's portfolio value fell 6.9% quarter-over-quarter to $335M.

Based on Prosight Management's 13F filing for Q2 2024, filed 14 Aug 2024.